Gilmore O’Neill, Editas Medicine CEO
Editas reports early-stage data from two patients in sickle cell disease
One company is moving forward in its bid to make a cell therapy for sickle cell disease viable — and after previous setbacks, including a hold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
